Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.

Lele ZhangJiacheng HuangXiaona ChenCaixu PanYong HeRong SuDanjing GuoShengyong YinShuai WangLin ZhouJianxiang ChenShusen ZhengYiting Qiao

Published in: Journal for immunotherapy of cancer (2022)

In summary, this study offers an efficient codelivery platform for neoantigens and immunoregulatory compounds to enhance immune responses during cancer immune therapy.

Keyphrases

immune response
toll like receptor
dendritic cells
papillary thyroid
cell proliferation
inflammatory response
squamous cell carcinoma
stem cells
young adults
childhood cancer